Table 3 Multivariate analysis of 120-month cancer-specific survival (CSS) and overall survival (OS) of CRC patients in the combined cohort

Age (<65 vs. ≥65)

1.69

0.93–3.06

0.083

2.29

1.36–3.87

0.002

Tumour invasion (T1–T2 vs. T3–T4)

0.64

0.31–1.30

0.217

0.71

0.41–1.23

0.220

Nodal metastases (N0 vs. N1–N2)

3.98

1.81–8–74

0.001

2.23

1.28–3.88

0.005

Distant metastases (M0 vs. M1)

6.09

3.16–11.7

6.8E–8

3.83

2.19–6.72

2.8E–6

Lymphatic invasion (No vs. Yes)

1.36

0.62–2.96

0.443

1.12

0.64–1.97

0.693

Grade (1–2 vs. 3)

2.10

1.30–3.39

0.002

1.83

1.26–2.65

0.001

mGPS (0 vs. 1–2)

1.03

0.55–3.39

0.931

1.37

0.82–2.29

0.227

BRAF VE1 immunohistochemistry (negative vs. positive)

2.65

0.96–7.28

0.059

1.34

0.59–3.07

0.488

MMR status (proficient vs. deficient)

0.16

0.02–1.30

0.087

0.83

0.35–1.94

0.667

Immunoscore (0–1 vs. 2–4)

0.47

0.26–0.87

0.016

0.50

0.31–0.81

0.004

Serum MMP-8 (≤100 ng/mL vs. >100 ng/mL)

2.12

1.21–3.71

0.009

1.45

0.91–2.30

0.118